This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Leptin Fragment
Peptide fragments derived from the satiety hormone leptin, studied for their roles in appetite suppression, metabolic regulation, and potential therapeutic applications in obesity research.
Overview
Leptin fragments are peptide sequences derived from leptin, the 167-amino acid protein hormone primarily produced by white adipose tissue. Full-length leptin was discovered in 1994 by Jeffrey Friedman and colleagues through positional cloning of the ob (obese) gene in mice, a breakthrough that transformed the understanding of body weight regulation. Leptin fragments represent shorter peptide sequences from the parent protein that retain or modify specific biological activities.
Full-length leptin signals through the leptin receptor (Ob-R, also called LEPR) in the hypothalamus, primarily in the arcuate nucleus, to suppress appetite and increase energy expenditure. It functions as an adiposity signal — circulating levels are proportional to body fat mass, providing the brain with information about long-term energy stores. Leptin deficiency in both mice (ob/ob mice) and rare human cases leads to extreme obesity, which is completely reversed by leptin replacement therapy.
However, the majority of obese individuals have elevated leptin levels rather than deficiency, a condition termed "leptin resistance." This resistance involves impaired leptin transport across the blood-brain barrier, receptor desensitization, and disrupted intracellular signaling. Leptin fragments have been studied as potential approaches to overcome these resistance mechanisms, as smaller peptide sequences may have improved blood-brain barrier penetration or different receptor binding characteristics compared to the full-length protein.
Specific leptin fragments, including leptin (116-130) and other sequences, have been investigated in preclinical models for their ability to reduce food intake and body weight. Some fragments appear to retain anorexigenic activity while potentially avoiding the resistance mechanisms that limit full-length leptin's efficacy in obese individuals. Research into leptin fragments remains primarily preclinical, with the goal of identifying peptide sequences that could serve as templates for novel anti-obesity therapeutics.